Biology of Blood and Marrow Transplantation
Volume 16, Issue 7 , Pages 976-984 , July 2010

Chronic Kidney Disease, Thrombotic Microangiopathy, and Hypertension Following T Cell-Depleted Hematopoietic Stem Cell Transplantation

  • Ilya G. Glezerman

      Affiliations

    • Department of Medicine, Renal Service, Memorial Sloan Kettering Cancer Center, New York, New York
    • Corresponding Author InformationCorrespondence and reprint requests: Ilya G. Glezerman, MD, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065.
    • ,
  • Kenar D. Jhaveri

      Affiliations

    • Division of Nephrology and Hypertension, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York
    • ,
  • Thomas H. Watson

      Affiliations

    • Nephrology Associates, Birmingham, Alabama
    • ,
  • Alison M. Edwards

      Affiliations

    • Division of Biostatistics and Epidemiology, Department of Public Health, Weill Medical College of Cornell University, New York, New York
    • ,
  • Esperanza B. Papadopoulos

      Affiliations

    • Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York
    • ,
  • James W. Young

      Affiliations

    • Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York
    • ,
  • Carlos D. Flombaum

      Affiliations

    • Department of Medicine, Renal Service, Memorial Sloan Kettering Cancer Center, New York, New York
    • ,
  • Ann A. Jakubowski

      Affiliations

    • Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York

Received 8 May 2009 ,Accepted 3 February 2010.

References 

  1. Progress Report January-December 2008. Milwaukee, WI: Center for International Blood and Marrow Transplant Research; 2008;
  2. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341:14–21
  3. Ferry C, Gemayel G, Rocha V, et al. Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies. Bone Marrow Transplant. 2007;40:219–224
  4. Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14:658–663
  5. Kersting S, Hene RJ, Koomans HA, Verdonck LF. Chronic kidney disease after myeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:1169–1175
  6. Delgado J, Cooper N, Thomson K, et al. The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006;12:75–83
  7. Miralbell R, Bieri S, Mermillod B, et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol. 1996;14:579–585
  8. George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion. 2004;44:294–304
  9. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304
  10. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464–1472
  11. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267–276
  12. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254
  13. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266
  14. Collins NH, Fernandez J, Bleau S, et al. Comparison of bone marrow and G-CSF mobilized peripheral blood progenitor cells from single normal donors before and after T cell depletion. Cytotherapy. 1999;1:223
  15. Collins NH, Bleau SA, Kernan NA, O'Reilly Rj T. Cell depletion of bone marrow by treatment with soybean agglutinin and sheep red blood cell rosetting. In:  Areman E,  Deeg HJ,  Sacher RA editor. Bone Marrow and Stem Cell Processing: Manual of Current Techniques. Philadelphia, PA: Davis; 1992;p. 171
  16. Jakubowski AA, Small TN, Young JW, et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood. 2007;110:4552–4559
  17. Cohen EP, Drobyski WR, Moulder JE. Significant increase in end-stage renal disease after hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2007;39:571–572
  18. Weiss AS, Sandmaier BM, Storer B, Storb R, McSweeney PA, Parikh CR. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant. 2006;6:89–94
  19. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12
  20. Leung N, Slezak JM, Bergstralh EJ, et al. Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. Am J Kidney Dis. 2005;45:102–111
  21. Siami K, Kojouri K, Swisher KK, Selby GB, George JN, Laszik ZG. Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study. Transplantation. 2008;85:22–28
  22. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant. 1994;14:495–504
  23. Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis. 2003;41:471–479
  24. Raife TJ, Lager DJ. Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects. Mayo Clin Proc. 2002;77:323–328
  25. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129–1136
  26. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:571–575
  27. Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92:95–100
  28. Kersting S, Verdonck LF. Stem cell transplantation nephropathy: a report of six cases. Biol Blood Marrow Transplant. 2007;13:638–643
  29. Cohen EP, Sumaili EK, Krzesinski JM, Delanaye P, Cavalier E, Beguin Y. Chronic kidney disease after hematopoietic stem cell transplantion: incindence, risk factors and survival. J Am Soc Nephrol. 2009;(Abstract Issue 20):244A

 Financial disclosure: See Acknowledgments on page 983.

 A.A.J. and C.F. share senior authorship.

PII: S1083-8791(10)00062-5

doi: 10.1016/j.bbmt.2010.02.006

Biology of Blood and Marrow Transplantation
Volume 16, Issue 7 , Pages 976-984 , July 2010

Article Tools

* Image Usage & Resolution